Discovery Knows No Bounds

Discovery knows no bounds

© Copyright 2019 Regenerative Medicine Minnesota

Targeting Adenosine A2A Receptor as a Novel Regenerative Therapy in Improving Chemobrain

Research Grant Recipient: Mi-Hyeon Jang, PhD

Award Value: $249,998

Research Focus: Cognitive dysfunction from chemotherapy

From the Investigator:

In the United States, cognitive dysfunction stemming from chemotherapy (chemobrain) is a major adverse condition affecting approximately 14 million cancer survivors with no known cure. Therefore, in this application, we aim to determine whether targeting the adenosine A2A receptor (Adora2a) is an effective regenerative strategy in promoting dendrite spine regeneration and improving chemotherapy-induced chemobrain. This understanding will provide insight into development of novel therapeutic interventions that prevent chemotherapy-induced cognitive dysfunction, thus resulting in a better quality of life for cancer survivors.